Autoimmunity Laboratory, Centre for Inflammatory Diseases, Department of Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria 3168, Australia.
Diabetes and Metabolism Division, Baker IDI Heart and Diabetes Institute, 75 Commercial Rd, Melbourne, Victoria 3004, Australia.
Genes (Basel). 2010 Sep 30;1(3):335-48. doi: 10.3390/genes1030335.
Cell Division Autoantigen 1 (CDA1) was discovered following screening a human expression library with serum from a patient with Discoid Lupus Erythematosus. CDA1, encoded by TSPYL2 on the X chromosome, shares anti-proliferative and pro‑fibrotic properties with TGF-b. It inhibits cell growth through p53, pERK1/2 and p21‑mediated pathways and is implicated in tumorigenesis and the DNA damage response. Its pro-fibrotic property is mediated through cross-talk with TGF-b that results in upregulation of extracellular matrix proteins. The latter properties have identified a key role for CDA1 in diabetes associated atherosclerosis. These dual properties place CDA1 as an attractive molecular target for treating tumors and vascular fibrosis including atherosclerosis and other vascular disorders associated with enhanced TGF-β action and tissue scarring.
细胞分裂自动抗原 1（CDA1）是在使用盘状红斑狼疮患者的血清筛选人类表达文库时发现的。CDA1 由 X 染色体上的 TSPYL2 编码，与 TGF-b 具有抗增殖和促纤维化特性。它通过 p53、pERK1/2 和 p21 介导的途径抑制细胞生长，并且与肿瘤发生和 DNA 损伤反应有关。其促纤维化特性是通过与 TGF-b 的交叉对话介导的，导致细胞外基质蛋白的上调。这些特性确定了 CDA1 在糖尿病相关动脉粥样硬化中的关键作用。这些双重特性使 CDA1 成为治疗肿瘤和血管纤维化（包括动脉粥样硬化和其他与增强 TGF-β 作用和组织瘢痕形成相关的血管疾病）的有吸引力的分子靶标。
